The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
💡 한 문장 핵심
양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
무작위 임상시험
5/5 보강
TL;DR
Among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduces the risk of surgery and acute urinary retention.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
surgery for benign prostatic hyperplasia (reduction in risk with finasteride, 55 percent; 95 percent confidence interval, 41 to 65 percent)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Treatment with finasteride also significantly improved urinary flow rates and reduced prostate volume (P<0.001). [CONCLUSIONS] Among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduces the risk of surgery and acute urinary retention.
📑 코퍼스 인용 관계
· 인용됨 32
📑 인용한 논문 (6) ▾
- SRD5A2 and emerging therapies in androgen-driven disorders. Nature reviews. Urology · 2026
- Management of Lower Urinary Tract Symptoms in Patients on Active Surveillance for Prostate… Current urology reports · 2026
- Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Beni… The world journal of men's health · 2025
- The post-finasteride syndrome: possible etiological mechanisms and symptoms. International journal of impotence research · 2025
- C.A. meyer alleviates benign prostatic hyperplasia while preventing finasteride-induced s… Frontiers in pharmacology · 2023
- Synthesis and Evaluation of Finasteride-Loaded HPMC-Based Nanogels for Transdermal Deliver… BioMed research international · 2022
연도별 인용 (2012–2026) · 합계 394
OpenAlex 토픽 ·
Urinary Bladder and Prostate Research
Pelvic floor disorders treatments
Prostate Cancer Diagnosis and Treatment
🇰🇷 한글 요약 🌐 Abstract
【연구 목적】
양성 전립선비대증(benign prostatic hyperplasia, BPH) 환자에서 피나스테리드(finasteride) 5mg 4년 장기 투여가 비뇨기 증상 개선 효과를 지속시키고, 수술 및 급성 요폐(acute urinary retention) 발생 위험을 줄이는지 평가하고자 함.
【방법】
중등도~중증 배뇨 증상과 전립선 비대를 동반한 남성 3,040명을 대상으로 한 이중맹검 무작위 위약대조 시험으로, 피나스테리드 5mg 또는 위약을 4년간 매일 투여하고 4개월마다 증상 점수(1~34점), 요속, 임상사건을 평가함. 일부 환자에서 전립선 용적을 측정함.
【주요 결과】
4년간 BPH 수술률은 위약군 10%(152/1,503), 피나스테리드군 5%(69/1,513)로 위험이 55% 감소(95% CI 41~65%)했고, 급성 요폐 발생률도 위약군 7%에서 피나스테리드군 3%로 57% 감소(95% CI 40~69%)함. 증상 점수는 피나스테리드군 3.3점, 위약군 1.3점 감소(P<0.001)했으며 요속 증가와 전립선 용적 감소도 유의했음.
【임상적 시사점 (성형외과 의사 관점)】
피나스테리드는 5α-환원효소 억제제로 모발이식 및 남성형 탈모(androgenetic alopecia) 치료 시 1mg 용량으로 흔히 처방되는데, 본 5mg BPH 연구는 동일 성분의 장기 안전성·내약성 데이터를 뒷받침함. 다만 탈모 클리닉 운영 시 고령 환자에게는 BPH 동반 여부를 문진하고, PSA 수치가 약 50% 감소할 수 있어 전립선암 선별검사 해석 시 보정이 필요함을 환자에게 안내해야 함.
[BACKGROUND] Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention, is not known.
[METHODS] In this double-blind, randomized, placebo-controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily with 5 mg of finasteride or placebo for four years. Symptom scores (on a scale of 1 to 34), urinary flow rates, and the occurrence of outcome events were assessed every four months in 3016 men. Prostate volume was measured in a subgroup of the men. Complete data on outcomes were available for 2760 men.
[RESULTS] During the four-year study period, 152 of the 1503 men in the placebo group (10 percent) and 69 of the 1513 men in the finasteride group (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with finasteride, 55 percent; 95 percent confidence interval, 41 to 65 percent). Acute urinary retention developed in 99 men (7 percent) in the placebo group and 42 men (3 percent) in the finasteride group (reduction in risk with finasteride, 57 percent; 95 percent confidence interval, 40 to 69 percent). Among the men who completed the study, the mean decreases in the symptom score were 3.3 in the finasteride group and 1.3 in the placebo group (P<0.001). Treatment with finasteride also significantly improved urinary flow rates and reduced prostate volume (P<0.001).
[CONCLUSIONS] Among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduces the risk of surgery and acute urinary retention.
[METHODS] In this double-blind, randomized, placebo-controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily with 5 mg of finasteride or placebo for four years. Symptom scores (on a scale of 1 to 34), urinary flow rates, and the occurrence of outcome events were assessed every four months in 3016 men. Prostate volume was measured in a subgroup of the men. Complete data on outcomes were available for 2760 men.
[RESULTS] During the four-year study period, 152 of the 1503 men in the placebo group (10 percent) and 69 of the 1513 men in the finasteride group (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with finasteride, 55 percent; 95 percent confidence interval, 41 to 65 percent). Acute urinary retention developed in 99 men (7 percent) in the placebo group and 42 men (3 percent) in the finasteride group (reduction in risk with finasteride, 57 percent; 95 percent confidence interval, 40 to 69 percent). Among the men who completed the study, the mean decreases in the symptom score were 3.3 in the finasteride group and 1.3 in the placebo group (P<0.001). Treatment with finasteride also significantly improved urinary flow rates and reduced prostate volume (P<0.001).
[CONCLUSIONS] Among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduces the risk of surgery and acute urinary retention.
- p-value P<0.001
【연구 목적】 양성 전립선비대증(benign prostatic hyperplasia, BPH) 환자에서 피나스테리드(finasteride) 5mg 4년 장기 투여가 비뇨기 증상 개선 효과를 지속시키고, 수술 및 급성 요폐(acute urinary retention) 발생 위험을 줄이는지 평가하고자 함.
APA 7
McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., Taylor, A. M., & Waldstreicher, J. (1998). The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group.. The New England journal of medicine, 338(9), 557-63. https://doi.org/10.1056/NEJM199802263380901
Vancouver
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. New Engl. jour. medi.. 1998;338(9):557-63. doi:10.1056/NEJM199802263380901
AMA 11
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. New Engl. jour. medi.. 1998;338(9):557-63. doi:10.1056/NEJM199802263380901
Chicago
McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., and .... 1998. "The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group." The New England journal of medicine 338 (9): 557-63. https://doi.org/10.1056/NEJM199802263380901
MLA 9
McConnell, J. D., et al. "The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group." The New England journal of medicine, vol. 338, no. 9, 1998, pp. 557-63. doi:10.1056/NEJM199802263380901.
PMID
9475762 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 20
- Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
- Finasteride for benign prostatic hyperplasia.
- Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a seri…
- Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.
- Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link?
- Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of random…
- Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
- Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries…
- Atypical post-finasteride syndrome: A pharmacological riddle.
- Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.
- Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alp…
- Comparison of clinical trials with finasteride and dutasteride.
- Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.
- Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia:…
- The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, …
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment o…
- Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BP…
- The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate canc…
- The post-finasteride syndrome: possible etiological mechanisms and symptoms.
- C.A. meyer alleviates benign prostatic hyperplasia while preventing finasteride-induced side effect…
같은 제1저자의 인용 많은 논문 (5)
- The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
- Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
- Benign prostatic hyperplasia. Hormonal treatment.
- Androgen ablation and blockade in the treatment of benign prostatic hyperplasia.
- BPH: what really works?